|
1
|
Corbex M, Bouzbid S, Traverse-Glehen A,
Aouras H, McKay-Chopin S, Carreira C, Lankar A, Tommasino M and
Gheit T: Prevalence of papillomaviruses, polyomaviruses, and
herpesviruses in triple-negative and inflammatory breast tumors
from algeria compared with other types of breast cancer tumors.
PLoS One. 9:e1145592014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Collignon J, Lousberg L, Schroeder H and
Jerusalem G: Triple-negative breast cancer: Treatment challenges
and solutions. Breast Cancer (Dove Med Press). 8:93–107.
2016.PubMed/NCBI
|
|
3
|
Maia AR, de Man J, Boon U, Janssen A, Song
JY, Omerzu M, Sterrenburg JG, Prinsen MB, Willemsen-Seegers N, de
Roos JA, et al: Inhibition of the spindle assembly checkpoint
kinase TTK enhances the efficacy of docetaxel in a triple-negative
breast cancer model. Ann Oncol. 26:2180–2192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sikov WM, Berry DA, Perou CM, Singh B,
Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER,
et al: Impact of the addition of carboplatin and/or bevacizumab to
neoadjuvant once-per-week paclitaxel followed by dose-dense
doxorubicin and cyclophosphamide on pathologic complete response
rates in stage II to III triple-negative breast cancer: CALGB 40603
(Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ali AM, Ansari JA, El-Aziz NMA, Abozeed
WN, Warith AMA, Alsaleh K and Nabholtz JM: Triple negative breast
cancer: A tale of two decades. Anticancer Agents Med Chem.
17:491–499. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qi MS and Elion EA: MAP kinase pathways. J
Cell Sci. 18:3569–3572. 2015.
|
|
7
|
Zhang Y, Wei L, Yu J, Li G, Zhang X, Wang
A, He Y, Li H and Yin D: Targeting of the β6 gene to suppress
degradation of ECM via inactivation of the MAPK pathway in breast
adenocarcinoma cells. Oncol Rep. 32:1787–1795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cotrim CZ, Fabris V, Doria ML, Lindberg K,
Gustafsson JÅ, Amado F, Lanari C and Helguero LA: Estrogen receptor
beta growth-inhibitory effects are repressed through activation of
MAPK and PI3K signalling in mammary epithelial and breast cancer
cells. Oncogene. 32:2390–2402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Borah N, Gunawardana S, Torres H,
McDonnell S and Van Slambrouck S: 5,6,7,3′,4′,5′-Hexamethoxyflavone
inhibits growth of triple-negative breast cancer cells via
suppression of MAPK and Akt signaling pathways and arresting cell
cycle. Int J Oncol. 51:1685–1693. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nalwoga H, Arnes JB, Wabinga H and Akslen
LA: Expression of EGFR and c-kit is associated with the basal-like
phenotype in breast carcinomas of African women. APMIS.
116:515–525. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Normanno N, Campiglio M, Maiello MR, De
Luca A, Mancino M, Gallo M, D'Alessio A and Menard S: Breast cancer
cells with acquired resistance to the EGFR tyrosine kinase
inhibitor gefitinib show persistent activation of MAPK signaling.
Breast Cancer Res Treat. 112:25–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abdelrahman AE, Rashed HE, Abdelgawad M
and Abdelhamid MI: Prognostic impact of EGFR and cytokeratin 5/6
immunohistochemical expression in triple-negative breast cancer.
Ann Diagn Pathol. 28:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi Y, Yang F, Huang D and Guan X:
Androgen blockade based clinical trials landscape in triple
negative breast cancer. Biochim Biophys Acta Rev Cancer.
1870:283–290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim S, You D, Jeong Y, Yu J, Kim SW, Nam
SJ and Lee JE: Berberine down-regulates IL-8 expression through
inhibition of the EGFR/MEK/ERK pathway in triple-negative breast
cancer cells. Phytomedicine. 50:43–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gholami S, Chen CH, Gao S, Lou E, Fujisawa
S, Carson J, Nnoli JE, Chou TC, Bromberg J and Fong Y: Role of MAPK
in oncolytic herpes viral therapy in triple-negative breast cancer.
Cancer Gene Ther. 21:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giltnane JM and Balko JM: Rationale for
targeting the Ras/MAPK pathway in triple-negative breast cancer.
Discov Med. 17:275–283. 2014.PubMed/NCBI
|
|
17
|
Zhao M, Howard EW, Parris AB, Guo Z, Zhao
Q and Yang X: Alcohol promotes migration and invasion of
triple-negative breast cancer cells through activation of p38 MAPK
and JNK. Mol Carcinog. 56:849–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oh AS, Lorant LA, Holloway JN, Miller DL,
Kern FG and El-Ashry D: Hyperactivation of MAPK induces loss of
ERalpha expression in breast cancer cells. Mol Endocrinol.
15:1344–1359. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Majorini MT, Manenti G, Mano M, De Cecco
L, Conti A, Pinciroli P, Fontanella E, Tagliabue E, Chiodoni C,
Colombo MP, et al: cIAP1 regulates the EGFR/Snai2 axis in
triple-negative breast cancer cells. Cell Death Differ.
25:2147–2164. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jing W: Expression and significance of
MAPK protein in breast cancer. Journal of Ningxia Medical College.
36:743–745. 2014.(In Chinese).
|
|
21
|
Zenzola V, Cabezas-Quintario MA, Arguelles
M, Pérez-Fernández E, Izarzugaza Y, Correa A and García-Foncillas
J: Prognostic value of Ki-67 according to age in patients with
triple-negative breast cancer. Clin Transl Oncol. 20:1448–1454.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Walsh EM, Shalaby A, O'Loughlin M, Keane
N, Webber MJ, Kerin MJ, Keane MM, Glynn SA and Callagy GM: Outcome
for triple negative breast cancer in a retrospective cohort with an
emphasis on response to platinum-based neoadjuvant therapy. Breast
Cancer Res Treat. 174:1–13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Evans MK, Brown MC, Geradts J, Bao X,
Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine
H, et al: XIAP regulation by MNK links MAPK and NFκB signaling to
determine an aggressive breast cancer phenotype. Cancer Res.
78:1726–1738. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu W, Zhang L, Shi J, Liu Y, Zhou L, Hou
K, Qu X and Teng Y: Clinical significance of pAkt and pErk1/2
expression in early-stage breast cancer patients treated with
anthracycline-based adjuvant chemotherapy. Oncol Lett. 9:1707–1714.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ono H, Sowa Y, Horinaka M, Iizumi Y,
Watanabe M, Morita M, Nishimoto E, Taguchi T and Sakai T: The
histone deacetylase inhibitor OBP-801 and eribulin synergistically
inhibit the growth of triple-negative breast cancer cells with the
suppression of survivin, Bcl-xL, and the MAPK pathway. Breast
Cancer Res Treat. 171:43–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Uehara N, Kanematsu S, Miki H, Yoshizawa K
and Tsubura A: Requirement of p38 MAPK for a cell-death pathway
triggered by vorinostat in MDA-MB-231 human breast cancer cells.
Cancer Lett. 315:112–121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng B, He R, Xu Q, Yang Y, Hu Q, Hou H,
Liu X and Li J: Ginsenoside 20(S)-protopanaxadiol inhibits
triple-negative breast cancer metastasis in vivo by targeting
EGFR-mediated MAPK pathway. Pharmacol Res. 142:1–13. 2019.
View Article : Google Scholar : PubMed/NCBI
|
